期刊
JOURNAL OF RHEUMATOLOGY
卷 39, 期 2, 页码 276-285出版社
J RHEUMATOL PUBL CO
DOI: 10.3899/jrheum.110765
关键词
BAYESIAN; PROPENSITY SCORE; PULMONARY HYPERTENSION; CONFOUNDING; SCLERODERMA; WARFARIN
类别
资金
- Canadian Institutes of Health Research
- Scleroderma Society of Ontario
- Abbott
- Arthritis Society, University of Toronto
Objective. Warfarin is recommended in systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) and idiopathic PAH (IPAH) to improve survival. There is no evidence to support this in SSc-PAH and the evidence in IPAH is conflicting. We evaluated the ability of warfarin to improve survival using 2 large SSc-PAH and IPAH cohorts. Methods. The effect of warfarin on all-cause mortality was evaluated. Bayesian propensity scores (PS) were used to adjust for baseline differences between patients exposed and not exposed to warfarin, and to assemble a matched cohort. Bayesian Cox proportional hazards models were constructed using informative priors based on international PAH expert elicitation. Results. Review of 1138 charts identified 275 patients with SSc-PAH (n = 78: 28% treated with warfarin) and 155 patients with IPAH (n = 91; 59% treated with warfarin). Baseline differences in PAN severity and medications were resolved using PS matching. In the matched cohort of 98 patients with SSc-PAH (49 treated with warfarin), the posterior median hazard ratio (HR) was 1.06 [95% credible interval (CrI) 0.70, 1.63]. In the matched cohort of 66 patients with IPAH (33 treated with warfarin), the posterior median HR was 1.07 (95% CrI 0.57, 1.98). The probability that warfarin improves median survival by 6 months or more is 23.5% in SSc-PAH and 27.7% in IPAH. Conversely, there is a > 70% probability that warfarin provides no significant benefit or is harmful. Conclusion. There is a low probability that warfarin improves survival in SSc-PAH and IPAH. Given the availability of other PAH therapies with demonstrable benefits, there is little reason to use warfarin to improve survival for these patients. (First Release Jan 15 2012: J Rheumatol 2012:39:276-85; doi:10.3899/jrheum.110765)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据